Kornimate/medical-research-clean huggingface dataset:
intra-arterial magnesium administration for acute stroke

Conditions: Acute Stroke

Summary: stroke is the second leading cause of death and the leading cause of adult disability worldwide. this investigation will address the safety and feasibility of directed, intra-arterial magnesium measurement and therapy, through endovascular access, in acute stroke patients. the proposal represents the first study to directly quantify levels of a systemically administered neuroprotectant in the region of cerebral ischemia. it also establishes a novel endovascular platform for direct delivery of neuroprotective agents to ischemic cerebral tissue distal to an occlusive thrombus. this research seeks to improve patient care by establishing a novel delivery mechanism for the rescue of threatened brain parenchyma that can be administered rapidly following acute stroke. if successful, this selective distribution will allow delivery to "at risk" tissue in a rapid manner. salvage of viable, but threatened, penumbral tissue could afford stroke patients an increased probability of favorable long term outcome. the investigators hypothesize that endovascular, intra-arterial, magnesium administration will deliver high concentration of this neuroprotective agent to otherwise inaccessible cerebral territories, while limiting systemic concentrations. the proposed investigation will evaluate the safety and feasibility of this novel treatment technique


Eligibility criteria:
inclusion criteria: 1. patient with acute cerebral ischemia due to ica or mca occlusion, 2. patient's clinical attending physician plans mechanical embolectomy procedure as part of routine clinical care. 3. age 21-95. exclusion criteria: 1. severe renal impairment with creatinine 3.0 or higher, 2. myasthenia gravis, 3. second or third degree heart block without a pacemaker in place, 4. technical inability to navigate microcatheter to target clot, 5. patient already enrolled in another experimental treatment trial. exclusion criteria 1-3 are all contraindications to magnesium therapy.

Keywords: stroke magnesium endovascular
pesticides--health fertility and reproductive risk

Conditions: Birth Defects; Miscarriages; Cancer

Summary: this project is designed to establish whether pesticides or other environmental agents have a role in the excess birth defects identified in the red river valley of minnesota. in this human study, laboratory based health parameters will be used to key in health survey data. in vitro data will be developed to mechanistic information. concordant results among these study features will provide a weight of evidence approach.


Eligibility criteria:
pesticide applicators and their spouses

Keywords: population studies laboratory evaluation hormone analysis semen analysis chromosome studies
single dose ablative radiation treatment for early-stage breast cancer

Conditions: Breast Neoplasm

Summary: the purpose of the study is to investigate the feasibility of a preoperative, single dose, ablative partial breast radiation treatment in patients with early-stage breast cancer.

a total of twenty-five patients will be treated with a single dose preoperative ablative radiation treatment. after a vigilant follow-up with mri, breast conserving surgery will be performed 6 months after the ablative radiation treatment. the total follow-up time is 10 years. this study aims to present an ablative radiotherapy treatment approach that could resolve to some extent the disadvantages of current breast conserving treatment in elderly low-risk breast cancer patients who are currently not treated according to guidelines due to co-morbidity.

Eligibility criteria:
inclusion criteria: * who performance scale ≤2. * females at least 50 years of age with unifocal ct1n0 breast cancer or females at least 70 years of age with an unifocal ct1-2(maximum 3 cm)n0 breast cancer: - tumor size as assessed on mri * on tumor biopsy: * non-lobular invasive histological type carcinoma. * lcis is accepted. * er positive tumor receptor. * tumor negative sentinel node. * adequate communication and understanding skills of the dutch language. exclusion criteria: * legal incapacity * indication for chemotherapy or immunotherapy (i.e. patients with an indication for endocrine therapy are eligible) * brca gene mutation. * previous history of breast cancer * other type of malignancy within 5 years before breast cancer diagnosis. for adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin no specific time span from breast cancer diagnosis is required for inclusion * her2neu positive tumor. * previous history of ipsilateral breast surgery and impaired cosmetic outcome, as assessed by the treating surgeon or radiation-oncologist. * collagen synthesis disease. * signs of extensive dcis component on histological biopsy or mammogram. * invasive lobular carcinoma. * mri absolute contraindications as defined by the radiology department. * nodal involvement with cytological or histological confirmation. * treatment with neo-adjuvant systemic therapy.
ethical issues of using gene therapy in the treatment of amd

Conditions: Exudative Age-related Macular Degeneration

Summary: the objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (amd). this involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.

qualitative research based on semi-structured interviews conducted with patients diagnosed with age-related macular degeneration (amd), followed in the ophthalmology department of nantes university hospital and treated with intravitreal injections. these interviews are structured around three main themes in order to better understand: the experience and perception of the current treatment by the patients their perceptions, expectations, and potential concerns regarding gene therapy their perception and understanding of decision-making autonomy in their health decisions

Eligibility criteria:
inclusion criteria: * patients with exsudative amd, male female \>18 years patients for whom the doctor could consider gene therapy. exclusion criteria: patients with atrophic amd (age-related macular degeneration) patients with other degenerative retinal diseases than amd, patients with with associated cognitive disorders.

Keywords: ethical age-related macular degeneration
serum tweak levels in acne vulgaris

Conditions: Acne Vulgaris

Summary: evaluate the serum level of tweak in patients with av and their relations before and after treatment with isotretinoin.

acne vulgaris is a chronic inflammatory disease of the pilosebaceous follicles, characterized by comedones, papules, pustules, cysts, nodules, and occasionally scars. its pathogenesis includes follicular hyperkeratinization, sebaceous hypersecretion due to androgen stimulation, follicular colonization by propionibacterium acnes, immune and inflammatory responses. it affects the face, anterior chest, and upper back . inflammation is regarded as a key component in the pathogenesis of acne . an increase in the activity of the pro inflammatory cytokine, interleukin (il) 1, is observed before the beginning of hyperproliferation around the uninvolved follicles and is thought to trigger the activation of keratinocyte proliferation. nuclear factor kappa beta (nf κβ) regulated mrna gene levels of the cytokines tumour necrosis factor (tnf) α, il 1 β, il 8 and il 10 levels also affected. isotretinoin (13-cis retinoic acid) is a synthetic analog of vitamin a. its oral form is prescribed for severe cases which are resistant to other treatments. tumor necrosis factor (tnf)-like weak inducer of apoptosis (tweak) belongs to the tnf superfamily. it has an important role in the regulation of cell growth, apoptosis, angiogenesis, and immune reactions.

Eligibility criteria:
inclusion criteria: * patients classified according to the global acne grading system(gags) into moderate, severe, and very severe cases exclusion criteria: * pregnant and lactating women, patients with renal, git, skeletal, psychiatric, and endocrine disorders, sarcoidosis, and patients receiving drugs such as diuretics, multivitamins, anticonvulsants, glucocorticoids, erythromycin, estrogen compound pill were excluded.
study of the use of non-invasive ventilation in bronchial dilatation disease

Conditions: Bronchial Dilatation Disease; Bronchectasie

Summary: this is a medical record data collection study. the goal of this non-interventional and retrospective study is to describe the characteristics of the population currently being monitored for bronchial dilatation who have been treated with long-term niv. this is a study based on data from medical records. the assessment criteria will be : * epidemiological characteristics of the population with bronchial dilatation on long-term niv * reasons for initiation of niv * niv adjustment methods

non-invasive ventilation is a treatment sometimes used for severe severe bronchial dilatation, but to date there are no studies its efficacy. the expected results in this context are : * a description of the characteristics of patients with severe bronchial on non-invasive ventilation (niv) * a better understanding, during niv management, of the settings used, the tolerance and effectiveness of niv in reducing exacerbations, hospital admissions and patient mortality. * move towards better patient management data will be extracted from patient medical records and the pmsi.

Eligibility criteria:
inclusion criteria: * patients over 18 years * predominant diagnosis of bronchiectatic disease, excluding cystic fibrosis, confirmed by computed tomography * introduction of long-term niv at a given point in the patient's care exclusion criteria: * patient's opposition to participating in this study * cystic fibrosis * predominant diagnosis of copd or asthma, traction bronchiectasis, bronchiectasis resulting from focal endobronchial lesion, sarcoidosis or active allergic bronchopulmonary aspergillosis.

Keywords: bronchial dilatation disease non-invasive ventilation efficiency
earlobe crease as risk factors of acute myocardial infarction in chinese population

Conditions: Ear/*Abnormalities; Risk Factor

Summary: the purpose of this study is to explore the earlobe crease as a risk factor of acute myocardial infarction (ami)in the chinese population, combined with other risk factors, to predict high risk patients with coronary heart disease.

primary objectives: odds ratio and 95% confidence interval of binaural earlobe crease as risk factors of ami. secondary objectives: 1. to study the characteristics of different earlobe creases in different gender of the patients with ami. 2. to analyze the characteristics of earlobe crease in different age groups. 3. to compare the feature of earlobe crease in acute st elevation myocardial infarction and non st elevation myocardial infarction. 4. the sensitivity,specificity,positive likelihood ratio and negative likelihood ratio of binaural earlobe crease as risk factors of ami.

Eligibility criteria:
inclusion criteria: 1. initial acute myocardial infarction(ami). 2. detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin(ctn) with at least one value above the 99th percentile upper reference limit(url)) and with at least one of the following: * symptoms of ischemia * development of pathologic q waves in the electrocardiogram (ecg) * new or presumed new significant st-segment-t wave (st-t) changes or new left bundle branch block (lbbb). * identification of an intracoronary thrombus by angiography or autopsy * imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality. 3. type 1 (spontaneous myocardial infarction(mi)) in the third universal definition of mi: mi consequent to a pathologic process in the wall of the coronary artery (eg, plaque erosion/rupture, fissuring, or dissection), resulting in intraluminal thrombus. 4. infarct related artery (ira) showed that acute thrombus formation, ira occlusion or stenosis ≥95%、≥90%～95%、≤90%，thrombolysis in myocardial infarction(timi) 0-3 flow. 5. signed informed consent. exclusion criteria: 1. combined valvular heart disease, cardiomyopathy, blood diseases, skin diseases, rheumatic diseases, ischemic cerebrovascular disease, tumor, etc. 2. previous myocardial infarction. 3. previous percutaneous coronary intervention(pci) and coronary artery bypass graft(cabg). 4. chronic total occlusion(cto)lesions. 5. ear malformation. 6. ocular diseases. 7. participating in a clinical study.

Keywords: earlobe crease acute myocardial infarction risk factor
the time point of carboprost methylate administration and perioperative complications

Conditions: Artificial Abortion, PONV(Post Operative Nausea and Vomiting)

Summary: artificial abortion is the most widely used procedure in termination of first-trimester pregnancy. cervical ripening before the operation guarantees operative convenience and decreases complications. an overstrained cervical dilation associates with uterine perforation, cervical laceration and cervical incompetence. to address the issue, various mechanical and pharmaceutical methods have been applied to prepare the cervix before transvaginal procedures. prostaglandin analogues (pgs) play an important role in ripening the cervix or promoting uterine contraction in gynecology and obstetrics. as most tissues express prostaglandin receptors, vomiting, nausea, fever, diarrhea and abdominal pain can hardly be avoided with pgs administration. longer pgs action contributes to better cervical ripening, but more uncomfortableness at the same time. these annoying symptoms may affect the participants' satisfaction and increase perioperative risks. to balance the safety and effectiveness of the surgery as well as patients' feeling, a proper timing for cervical ripening should be investigated. however, the administration timing of pgs has not reached a broad consensus, ranging from 16 hours to 2 hours before surgery. carboprost methylate (cm), a pg-f2α analogue, has been used nationwide for cervical ripening in china. to minimize the side effects of pgs without affecting cervical ripening, the investigators intended to explore shortening the action time of cm in cervical preparation before artificial abortion. thus, the investigators conducted this prospective cohort study and aimed to examine the efficacy of early and delayed vaginal administration of cm before surgery, and optimized both the perioperative safety and participants' convenience. the investigators hypothesize that early vaginal administration of cm would not affect the cervical ripening status, but will greatly reduce the unpleasant complications among the participants.


Eligibility criteria:
inclusion criteria: * age 18-59 * signed informed consent. * admitted to hospital for surgical termination of unplanned pregnancy * gestational weeks range between 7 to 10 * average diameter of the gestational sac was no larger than 4cm exclusion criteria: * massive vaginal bleeding * severe abdominal pain at admission (numerical rating scale, nrs\>3) * genital tract infection * contraindication of pgs (including uncontrolled hypertension, asthma, glaucoma, severe heart disease or allergy to prostaglandins, etc.) * prior history of vaginal delivery
rimonabant in obesity over a 2-year duration (rio-europe)

Conditions: Obesity

Summary: the primary objective was to assess the effect of sr141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. the main secondary objectives were to assess the effect of sr141716 on lipid parameters (hdl-c, tg), glucose tolerance status, the rate of patients with metabolic syndrome, waist circumference, glycemic parameters.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) e30 kg/m2 in patients with or without comorbidities, or bmi \>27 kg/m2 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia. * stable body weight (variation \<5 kg within 3 months prior to screening visit); exclusion criteria: * history of very low-calorie diet within 6 months prior to screening visit; or history of surgical procedures for body weight loss (eg, stomach stapling, bypass); * presence of any clinically significant psychiatric , neurological or endocrine disease * presence of treated or untreated type 1 or type 2 diabetes); * sbp \>165 mmhg and/or dbp \>105 mmhg on 2 consecutive visits from the screening to the inclusion visit; * history of myocardial infarction or unstable angina pectoris within 6 months prior to screening visit; and history of stroke within 6 months prior to screening visit; * administration of anti-obesity drugs or other drugs for body weight reduction within 3 months prior to screening visit; the investigator will evaluate whether there are other reasons why a patient may not participate.

Keywords: obesity risk factors
effects of teriparatide therapy for japanese

Conditions: Osteoporosis

Summary: in this study, the investigators would like to analyze the bone mineral density (bmd) , bone turnover makers, and fracture prevention effects of daily teriparatide in japanese patients under clinical practice. the participants are treated in the investigators hospital, who are under severe osteoporotic condition. several determinants were reported to be related to subsequent bmd increase, such as baseline bone turnover markers (btms), low bmd at baseline, age, prior treatment, but comprehensive discussion is lacking. specifically, there analyses were performed fragmentarily. the main objective of this study is to reveal the determinants of subsequent bmd increase and fracture preventing effect by teriparatide. next, in japan, as the baby boom generation retires, aging and depopulation occur rapidly. as a result, there is a lot of nursing home. but there are few reports concerning to the efficacy of teriparatide treatment in nursing home patients. the second objective is to reveal the efficacy of teriparatide for patients living nursing home, especially bmd changes, bone turnover makers change, and adverse events.

registry criteria: patients treated in the investigators hospital using teriparatide. enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low bmd (\< young adult mean 65%). interventions: blood analyses and dual-energy x-ray absorptiometry (dxa) every 4 months informed consent: written informed consent will be obtained. sample size: five-hundreds participants

Eligibility criteria:
inclusion criteria: * severe osteoporotic patients exclusion criteria: * cancer, hypercalcemia, etc (i.e. patients who could not use teriparatide)

Keywords: osteoporosis bmd teriparatide nursing home
defendo long term follow-up study in stage 1 nk patients

Conditions: Neurotrophic Keratitis

Summary: the primary objectives are to evaluate the long-term safety and efficacy of oxervate™ 0.002% (20 mcg/ml) cenegermin-bkbj ophthalmic solution in stage 1 neurotrophic keratitis (nk) patients who enrolled in the defendo study.

this clinical study will be a multi-center, open label, long term follow-up study of the patients who were enrolled in the defendo study who had stage 1 neurotrophic keratitis (nk) who were treated with oxervate™ 0.002% (20 mcg/ml) cenegermin-bkbj ophthalmic solution. the defendo long-term follow-up study will have follow-up with the patients at month 24-30 post-treatment in the defendo study: all patients will be evaluated in a real-world setting post the enrollment in the defendo study through 30 months. patients will be treated per standard of care as determined by the investigator and will document topical ophthalmic medications. the original defendo study duration was for a total of 34 weeks: a screening period of 2 weeks, followed by enrollment in 8 weeks of oxervate™ treatment and an off- treatment follow-up of 6 months. after completing enrollment in the original defendo study, patients will be invited to enter the defendo long- term follow-up study (all standard of care is permitted). two additional long-term follow-up visits will occur at 24- and 30-months to evaluate long-term clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. previously enrolled in the defendo study. 2. satisfy all informed consent requirements. the patient and/or his/her legal representative has read, signed, and dated the irb approved informed consent document before any study-related procedures are performed. 3. must have the ability and willingness to comply with study procedures. exclusion criteria: participating in another study that involves treating the study eye. a. participation in non-ocular studies is acceptable provided that the treatment is not considered to be confounding with the defendo long-term follow-up study, in the opinion of the investigator.

Keywords: stage 1 nk oxervate cenegermin nk defendo
management of cisplatin-ineligible patients with metastatic bladder cancer and the role of geriatric assessments

Conditions: Bladder Cancer; Metastatic Bladder Cancer; Unresectable Bladder Carcinoma; Urothelial Carcinoma

Summary: the goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. in this study, investigators are assessing the role of the survey, the geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.

in this prospective, observational study, investigators are assessing the optimal approach to treating bladder cancer in older participants with other disease that might put the participants at additional risk from cancer-directed treatments. investigators are specifically assessing the impact on adverse events, quality of life, and treatment outcomes. additionally, investigators are assessing the role of the survey, the geriatric-8, and its ability to predict outcomes in older participants. the research study procedures include screening for eligibility and completing questionnaires. participation in this research study is expected to last for up to 8 months. it is expected that about 180 people will take part in this research study. the national comprehensive cancer network and emd serono are supporting this research study by providing the necessary funds.

Eligibility criteria:
inclusion criteria: * age ≥65-years-old (study will limit total enrollment of patients between ages 65-70 to 20% of the total study population) * unresectable or metastatic bladder cancer with histologically proven urothelial carcinoma. any component of variant histology is allowed * cisplatin-ineligible as determined by the subject's primary oncologist * receiving treatment with chemotherapy (+/- immunotherapy maintenance), enfortumab vedotin-pembrolizumab combination therapy or immunotherapy alone * ability to understand and the willingness to sign a written informed consent document and to complete patient reported outcomes that will be in english or spanish either alone or with assistance of study researcher or family exclusion criteria: * subjects who elect to not undergo cancer-directed therapy * subjects obtaining their care outside of dfci or dfci affiliate sites * advanced cognitive impairment or inability to complete surveys * participants who are receiving any other investigational agents for this condition (if appropriate only).

Keywords: bladder cancer metastatic bladder cancer unresectable bladder carcinoma urothelial carcinoma